Interactive tool
Compounding Warning-Letter Search
Entity; issue; date; response; closeout; related inspection; source.
This tool runs entirely in your browser against the same canonical datasets that drive the visible pages and the public downloads, so the tool and the pages cannot disagree. It reports what a named public record says on the date it was checked. It issues no badge, score, ranking, or safety verdict of any kind.
Key findings
- A warning letter follows inspection or other evidence and requests corrective action within a stated period. It is a formal agency communication, not a court finding.
- Closeout status is decisive. FDA issues a closeout letter when it has evaluated corrective actions and found them adequate. A letter without closeout and a closed-out letter describe differe
- Scope matters. A letter about sterility practices at one facility says nothing about a different facility under the same ownership, because registration and inspection are facility specific.
- Reporting a resolved warning letter as a current finding is one of the most common and most damaging errors in this sector, and this platform separates the two explicitly.
- Entity-specific compliance with this standard is not asserted on this page.
| Entity | Verification Pending |
|---|---|
| Issue | Verification Pending |
| Date | Verification Pending |
| Response | Verification Pending |
| Closeout | Verification Pending |
| Related inspection | Verification Pending |
| Federal framework | License Verified FDA sources verified 2026-07-23 |
| Entity-specific data | Verification Pending |
Warning-letter search
A warning letter states an agency position on specific violations at a specific time. Without its closeout status, it does not describe current standing.
No verified warning-letter record is held at this snapshot. Search FDA's warning letter database directly.
| Record type | What it is | What it is not |
|---|---|---|
| Form 483 observation | An investigator's observation at an inspection | A final agency finding |
| Warning letter | A stated agency position on specific violations | A judicial determination |
| Closeout letter | FDA's record that issues were addressed | A statement that no issue ever existed |
| Open inspection | FDA has not determined whether further action follows | Evidence of a violation |
What a result from this tool means
What this means
- A warning letter states the agency's position on specific violations at a point in time.
- Closeout status determines whether the action is current or resolved.
- Scope is limited to the findings the letter actually states.
What this does not mean
- That a letter without closeout is necessarily still active.
- That a warning letter is a final adjudication.
- That the entity is 'noncompliant' in any general sense.
What this tool can and cannot settle
A lookup tool answers one question well and creates a temptation to over-read the answer. This one reports what a named public record says on the date it was captured. It does not assess, score, or certify anything, and a result is a starting point for verification rather than its conclusion.
The specific limit worth understanding: a snapshot is not a live query. FDA updates its outsourcing facility register weekly and state boards update continuously, so a result here confirms what the record said on the snapshot date and nothing about today. For anything consequential, go to the source register directly — every result links to it.
- Results reflect a dated snapshot, not a live query against the source register.
- FDA updates its outsourcing facility register weekly; state boards update continuously.
- Self-reported registration information on FDA's list has not been verified by FDA.
- Absence of a result is absence from this snapshot, not evidence that no record exists anywhere.
| Question | Can this tool answer it? | What actually answers it |
|---|---|---|
| Is this facility federally registered? | Yes, as of the snapshot date | FDA outsourcing facility register |
| Is its state licence current today? | No | The issuing state board's live register |
| Has it been inspected? | No | FDA inspection records |
| Were there Form 483 observations? | No | FDA inspection records |
| Is there an active warning letter? | No | FDA warning letter database |
| Is this pharmacy safe to use? | No — and no tool can | No public record answers this question |
Related records in this section
Section hub: Interactive tools · Methodology · Status definitions · Right to respond
Frequently asked questions
What does this page cover on compounding warning letter search?
Entity; issue; date; response; closeout; related inspection; source.
What is established about entity?
Entity is tracked as part of compounding warning letter search. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about issue?
issue is tracked as part of compounding warning letter search. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about date?
date is tracked as part of compounding warning letter search. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
Where does this tool get its data on compounding warning letter search?
From the same canonical datasets that drive the visible pages and the public downloads, so the tool and the pages cannot disagree.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.